- Home
- BVN vs GRFS Comparison
BVN vs GRFS Comparison
Compare BVN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVN | GRFS |
|---|---|---|
| Founded | 1953 | 1940 |
| Country | Peru | Spain |
| Employees | N/A | 23800 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.5B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BVN | GRFS |
|---|---|---|
| Price | $39.11 | $8.69 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $44.00 | $10.15 |
| AVG Volume (30 Days) | ★ 1.4M | 608.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.93% | 1.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.48 | $5.33 |
| Revenue Next Year | N/A | $6.50 |
| P/E Ratio | $21.78 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $6.19 |
| 52 Week High | $44.67 | $11.14 |
Technical Indicators
Market Signals| Indicator | BVN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 39.04 |
| Support Level | $35.47 | $8.66 |
| Resistance Level | $41.00 | $9.11 |
| Average True Range (ATR) | 2.03 | 0.27 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 42.39 | 27.18 |
Price Performance
Historical ComparisonAbout BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.